By Matt Grossman

 

Biogen Inc. on Thursday raised its full-year adjusted-earnings guidance, leaving its revenue forecast unchanged.

The Cambridge, Mass.-based pharmaceutical company said it now expects full-year adjusted earnings of $17.50 to $19 a share, compared with a prior forecast for $17 to $18.50 a share. Analysts surveyed by FactSet had been estimating full-year adjusted earnings of $18.33 a share.

Biogen continues to expect revenue of $10.45 billion to $10.75 billion. Analysts' consensus is for revenue of $10.54 billion.

The company's guidance incorporates an expectation that U.S. regulators will approve aducanumab, a potential treatment for Alzheimer's disease, by June 7. If approved, the drug would launch immediately and contribute modest revenue this year, Biogen said.

 

Write to Matt Grossman at matt.grossman@wsj.com

 

(END) Dow Jones Newswires

April 22, 2021 07:56 ET (11:56 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Biogen Charts.
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Biogen Charts.